INTRODUCTION: Candidacy for deep brain stimulation (DBS) in Parkinson disease (PD) is typically assessed by the preoperative motor response to levodopa along with an interdisciplinary evaluation. However, recent cases treated at our institution have achieved good outcomes with DBS despite a sub-30% improvement in motor scores. The aim of this study was to examine the outcomes of DBS in a subset of patients who failed to reach the 30% motor improvement threshold. METHODS: A review of all DBS patients treated at the University of Florida Movement Disorders Center between 2002 and 2009 was performed utilizing a DBS database. All patients with sub-30% improvement in Unified Parkinson Disease Rating Scale Part III after dopaminergic medication administration were included. RESULTS: Nine patients were identified; DBS was performed for severe dyskinesia (n=5), "on/off motor" fluctuations (n=1) and medication-refractory tremor (n=3). The target symptoms were improved in all patients. Postoperatively, scores on the Unified Parkinson Disease Rating Scale Part II and III and subscores on Parkinson disease questionnaire-39 improved (P<0.05). CONCLUSIONS: Although motor response to levodopa remains the primary selection criteria for DBS candidacy in Parkinson disease, patients who do not meet the 30% threshold and have disabling symptoms may still benefit from DBS. Select patients with severe dyskinesia, "on/off" motor fluctuations, and/or medication-refractory tremor may experience significant benefits from DBS and should be considered on a case by case basis through an interdisciplinary team evaluation.
INTRODUCTION: Candidacy for deep brain stimulation (DBS) in Parkinson disease (PD) is typically assessed by the preoperative motor response to levodopa along with an interdisciplinary evaluation. However, recent cases treated at our institution have achieved good outcomes with DBS despite a sub-30% improvement in motor scores. The aim of this study was to examine the outcomes of DBS in a subset of patients who failed to reach the 30% motor improvement threshold. METHODS: A review of all DBS patients treated at the University of Florida Movement Disorders Center between 2002 and 2009 was performed utilizing a DBS database. All patients with sub-30% improvement in Unified Parkinson Disease Rating Scale Part III after dopaminergic medication administration were included. RESULTS: Nine patients were identified; DBS was performed for severe dyskinesia (n=5), "on/off motor" fluctuations (n=1) and medication-refractory tremor (n=3). The target symptoms were improved in all patients. Postoperatively, scores on the Unified Parkinson Disease Rating Scale Part II and III and subscores on Parkinson disease questionnaire-39 improved (P<0.05). CONCLUSIONS: Although motor response to levodopa remains the primary selection criteria for DBS candidacy in Parkinson disease, patients who do not meet the 30% threshold and have disabling symptoms may still benefit from DBS. Select patients with severe dyskinesia, "on/off" motor fluctuations, and/or medication-refractory tremor may experience significant benefits from DBS and should be considered on a case by case basis through an interdisciplinary team evaluation.
Authors: Elena Moro; Andres M Lozano; Pierre Pollak; Yves Agid; Stig Rehncrona; Jens Volkmann; Jaime Kulisevsky; Jose A Obeso; Alberto Albanese; Marwan I Hariz; Niall P Quinn; Jans D Speelman; Alim L Benabid; Valerie Fraix; Alexandre Mendes; Marie-Laure Welter; Jean-Luc Houeto; Philippe Cornu; Didier Dormont; Annalena L Tornqvist; Ron Ekberg; Alfons Schnitzler; Lars Timmermann; Lars Wojtecki; Andres Gironell; Maria C Rodriguez-Oroz; Jorge Guridi; Anna R Bentivoglio; Maria F Contarino; Luigi Romito; Massimo Scerrati; Marc Janssens; Anthony E Lang Journal: Mov Disord Date: 2010-04-15 Impact factor: 10.338
Authors: M L Welter; J L Houeto; S Tezenas du Montcel; V Mesnage; A M Bonnet; B Pillon; I Arnulf; B Pidoux; D Dormont; P Cornu; Y Agid Journal: Brain Date: 2002-03 Impact factor: 13.501
Authors: Paul Krack; Alina Batir; Nadège Van Blercom; Stephan Chabardes; Valérie Fraix; Claire Ardouin; Adnan Koudsie; Patricia Dowsey Limousin; Abdelhamid Benazzouz; Jean François LeBas; Alim-Louis Benabid; Pierre Pollak Journal: N Engl J Med Date: 2003-11-13 Impact factor: 91.245
Authors: Takashi Morishita; Sarah M Fayad; Masa-aki Higuchi; Kelsey A Nestor; Kelly D Foote Journal: Neurotherapeutics Date: 2014-07 Impact factor: 7.620
Authors: Gregory Brown; Guangwei Du; Elana Farace; Mechelle M Lewis; Paul J Eslinger; James McInerney; Lan Kong; Runze Li; Xuemei Huang; Sol De Jesus Journal: J Parkinsons Dis Date: 2022 Impact factor: 5.520
Authors: Kelsey A Nestor; Jacob D Jones; Christopher R Butson; Takashi Morishita; Charles E Jacobson; David A Peace; Dennis Chen; Kelly D Foote; Michael S Okun Journal: PLoS One Date: 2014-04-01 Impact factor: 3.240
Authors: Richard B Dewey; Padraig E O'Suilleabhain; Manjit Sanghera; Neepa Patel; Pravin Khemani; Laura H Lacritz; Shilpa Chitnis; Louis A Whitworth; Richard B Dewey Journal: PLoS One Date: 2016-10-06 Impact factor: 3.240